Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tenofovir Alafenamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,603Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Biktarvy

    02 5Descovy

    03 5Genvoya

    04 5Odefsey

    05 2Revenue share - Symtuza

    06 3Symtuza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Odefsey

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,672

    2019 Revenue in Millions : 1,655

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Biktarvy

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Biktarvy

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 7,259

    2019 Revenue in Millions : 4,738

    Growth (%) : 53

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Genvoya

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 3,338

    2019 Revenue in Millions : 3,931

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Symtuza

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Descovy

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,861

    2019 Revenue in Millions : 1,500

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Descovy

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 1,700

    2020 Revenue in Millions : 1,861

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Symtuza

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 531

    2020 Revenue in Millions : 488

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Odefsey

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 1,568

    2020 Revenue in Millions : 1,672

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Genvoya

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,879

    2020 Revenue in Millions : 3,338

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Odefsey

    Tenofovir Alafenamide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Gilead

    Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 1,469

    2021 Revenue in Millions : 1,568

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF